22% of share float is short? could see some short covering in advance of Nov 8 presentation.
"We look forward to sharing the first clinical data for AG-120 in patients with advanced solid tumors as we continue to understand the potential of this investigational medicine," said Chris Bowden M.D., chief medical officer at Agios. "This is an important step toward our long-term vision of making a difference for people with a broad range of hematologic and solid tumor cancers that harbor IDH mutations."
If we don't win this mega contract how low do you think BA will slide? If we win, what kind of bump makes sense? Thanks for your insight.
This $100Billion contract will be announced Tues after the bell. Will it be BA/LMT or NOC? Is that win or loss already factored into the stock price. Some believe BA has lead experience in composites. Whatdoyathink?
I am long agio and it has decline severely in the past few months. What insights do you celg shareholders have on the attractiveness of agio for continued partnership/acquisition with celg? thanks
(CONTINUED)The United States, the main driver of the 12-nation TPP free-trade pact, is seeking longer protections than the five years common in many countries.
In the US, pharmaceutical companies get 12 years of IP protection before rivals can produce "biosimilar" copycat drugs that sell more cheaply. But in most countries, the US protections for drug developers are seen as far too long, and costly, for health care systems.
The issue has raised objections from civil society groups and government health programs across many of the countries involved in the negotiations.
Rather than a problem of just cutting tariff or other trade barriers, lengthening protections would in many places require changing well-established national laws and IP protection policies
October 2, 2015 7:33 PM
US Trade Representative Michael Froman (C) takes a break from negotiations on the Trans-Pacific Partnership trade treaty in Atlanta, Georgia to visit the Colgate mattress factory on October 1, 2015
Atlanta (AFP) - Negotiations on the huge Pacific trade deal spilled into overtime on Friday with negotiators mainly stuck on how much patent protection to give biologic drugs.
The arrival of senior US congressional aides at the hotel site of the Trans-Pacific Partnership in Atlanta pointed to the possibility that top trade officials from 12 countries were close to a deal.
But their presence also underscored the stakes in the ambitious US-led attempt to create a Pacific Rim free-trade zone that would comprise 40 percent of the world's economy.
Pressure was intense on negotiators, especially those from the Australia, Canada, Japan, New Zealand and the United States to not undercut important home businesses as they bargain over the remaining issues involving the auto and dairy trades and protections for the drug patents of pharmaceutical companies.
Although the auto and dairy trade issues remained table, officials involved said the main barrier to a final deal is the length of intellectual property (IP) protection for biologics, a promising class of treatments derived from living materials.
The United States, the main driver of the 12-nation TPP free-trade pact, is seeking longer protections than the five years common in many countries.
In the US, pharmaceutical companies get 12 years of IP protection before rivals can produce "biosimilar" copycat drugs that sel
Agio CEO very positive on vision. Encouraged all to listen to the OCT 16th R&D day where the focus will be on investors to understand the key biology an how to link that to future direction.
TPB: wild card is CELG that could swoop in at anytime (like down here at 74) and do their acquisition of AGIO, well in advance of published solid tumor results. Just my thoughts, welcome yours.
trading pro: how much farther down do you see agio falling? do you expect it to bounce from that point? how much further down do you expect Dow and Nasdaq to fall? thanks.
...looks to me that the folks on margin are being squeezed with margin calls. Not excessive volume as agio seems to be about on its daily 3 month average shares traded.